



2/7/2025

Notice Regarding Offer of Refunds to 340B Covered Entities

GlaxoSmithKline (“GSK”) recently recalculated 340B Ceiling Prices for the NDCs referenced below for the time period of July 1, 2023 through September 30, 2023 (3Q2023). As a result of the recalculation, GSK has determined that (pursuant to 42 U.S.C. § 256b(d)(1)(B)(ii) and 42 C.F.R. § 10.11(b)(4)), a refund is or may be due to any 340B Covered Entity which purchased any of the below NDCs during the aforementioned time period.

The table below identifies the NDCs that are subject to a refund. The recalculated Ceiling Prices are the result of revised pricing data that were submitted to the Centers for Medicare & Medicaid Services.

Time Period	Product	NDC-11
07/01/2023 – 09/30/2023	IMITREX INJ STATDOSE SYSTEM 4MG/0.5ML 1S	00173-0739-00
07/01/2023 – 09/30/2023	IMITREX INJ STATDOSE REFILL 4MG/0.5ML 2S	00173-0739-02

GSK intends to refund any amount equal to or in excess of \$100 (aggregate for all applicable NDCs) for the periods listed directly to the 340B Covered Entity of record. Separate correspondence including a check and details of the payment will be sent to the qualifying 340B Covered Entity.

For 340B Covered Entities who may be owed less than \$100 in aggregate or who have questions about the above-referenced recalculation for this period, GSK invites interested parties to contact it via email at GSK.340BRefunds@gsk.com, with a reference to the NDC and time period.

GSK has asked the Health Resources and Services Administration (HRSA) to post this Notice on the HRSA’s public website to ensure transparency to all 340B Covered Entities regarding the Ceiling Price recalculations for all NDC’s identified above and to offer a refund to any of the 340B Covered Entities that may have purchased the above NDCs during the relevant time periods. Please direct any questions and/or requests for additional information to GSK at the following email address: GSK.340BRefunds@gsk.com.